A pioneer in CGT strategy with experience with key leaders in the field, Putnam has had a dedicated practice in this space since 2013. Our practice has covered 17 unique disease areas including hematologic malignancies (DLBCL, ALL, MM, FL), solid tumors, neurology, ophthalmology, cardiology, and benign blood disorders. Putnam’s in-house panel of CGT experts provides our teams with unfettered access to high-level KOLs, clinicians, and key administrative decision-makers (CMOs, SVPs, CFOs) at leading US medical centers. Our robust experience and industry leading breadth and depth across client types, diseases areas and technologies within this space allows us to support a wide array of CGT specific engagements:
- Commercial Opportunity Assessment
- Market Access & Pricing Strategy
- Business Development & Portfolio Planning
- Operations Customer Experience
